ARO-ANG 3 Injection ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 79 | Homozygous familial hypercholesterolemia | 1 |
79. Homozygous familial hypercholesterolemia
Clinical trials : 145 / Drugs : 114 - (DrugBank : 26) / Drug target genes : 8 - Drug target pathways : 17
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05217667 (ClinicalTrials.gov) | April 22, 2022 | 20/1/2022 | Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) | Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH) | Homozygous Familial Hypercholesterolemia | Drug: ARO-ANG 3 Injection | Arrowhead Pharmaceuticals | NULL | Active, not recruiting | 16 Years | N/A | All | 18 | Phase 2 | United States;Australia;Canada;South Africa |